Giloy: Benefits, Evidence & Safety

TL;DR

Giloy (Tinospora cordifolia) improved nasal symptoms in one small eight-week randomized trial of 75 patients with allergic rhinitis. Beyond that, human evidence is thin: most research is preclinical, and giloy has been linked to liver injury in case reports and a 43-patient multicenter study. It is not an established immune booster or liver tonic.

What it is

Giloy, also called guduchi, is Tinospora cordifolia (Willd.) Miers, a large deciduous vine whose thick, fleshy stems climb and trail over host trees (Heliyon review; multicenter liver-injury study). The two names are one plant: a 2023 case review's title pairs them as "Giloy/Guduchi" (PubMed). The stem is the part most described in Ayurvedic and review literature. Its powder tastes bitter, and traditional texts prescribe it for indigestion, fever, and urinary complaints (Heliyon review).

Traditional use

In Ayurveda, giloy belongs to the rasayana group: herbs taken to rebuild strength and balance after illness. Reviewers credit it with immune-modulating properties, but that is a traditional attribution, not a finding from human trials (Medicinal Plants review, 2023). A 2021 hepatology case series describes Tinospora cordifolia as "a widely grown shrub which has been commonly used in India's traditional system of Ayurveda for its immune booster properties" (J Clin Exp Hepatol). During the COVID-19 pandemic, giloy was widely advertised as an "immune-booster" (Hepatology Communications, 2022). Traditional reviews also list its use for digestive complaints and liver disorders (Heliyon review). These are traditional claims, not clinical proof: the trial evidence is assessed separately below.

What modern research says

Allergic rhinitis

The clearest human signal comes from a 2005 randomized, double-blind, placebo-controlled trial of 75 participants with allergic rhinitis. Over eight weeks, the Tinospora cordifolia extract group showed improvement in sneezing, nasal discharge, nasal obstruction and itching versus placebo, and the extract was reported as well tolerated (Badar et al., Journal of Ethnopharmacology).

A 2018 Clinical Phytoscience review of phytotherapy for allergic rhinitis independently cites this trial, stating that well-controlled studies "demonstrated statistically significant effects for ... Tinospora cordifolia ... in the improvements of several outcome measures, including nasal symptoms (rhinorrhoea, sneezing, obstruction and itching), peak nasal flow rate and mucociliary clearance time, as well as quality of life in allergic rhinitis patients" (Springer review). Caveats: this is a single small trial from 2005 with limited publicly available detail, and the finding needs replication before it can support confident claims.

HIV (adjunct study)

In a 2008 trial, 68 HIV-positive participants were randomized to a Tinospora cordifolia extract or placebo for six months. More symptom improvement was reported with the extract, but not all objective measures supported the effect, and complaints in the trial included anorexia, nausea, vomiting, and weakness. The authors suggested the extract "could be used as an adjunct" to HIV/AIDS management: not as a treatment, and never a replacement for antiretroviral therapy (Kalikar et al., Indian Journal of Pharmacology).

What the evidence does not support (yet)

Beyond the allergic-rhinitis trial above, human evidence is sparse. A 2022 nationwide multicenter study concluded that "studies on Giloy are mostly preclinical with no strong evidence for use in humans to prevent or treat any disease" (Hepatology Communications). Claims that giloy treats diabetes, cancer, viral illnesses (including COVID-19), or protects the liver are not established by clinical trials. Note the contradiction: giloy is traditionally associated with liver support, but the strongest modern clinical literature about it concerns liver injury (see Safety below).

Safety & contraindications

Liver injury is the major documented risk. A 2021 case series in the Journal of Clinical and Experimental Hepatology reported six patients who developed acute hepatitis-like illness after Tinospora cordifolia use, with autoimmune-like hepatitis or unmasking of underlying autoimmune liver disease (Nagral et al.).

A larger 2022 nationwide multicenter study in Hepatology Communications documented 43 patients with giloy-associated liver injury: the median time to symptom onset was 46 days after starting giloy, and presentations included acute hepatitis, worsening of chronic liver disease, and acute liver failure. Causality was judged probable in 67.4% of cases, and autoimmune features were common (Kulkarni et al.). A 2023 case review supports the possibility of idiosyncratic, immune-mediated giloy liver injury (PubMed).

Practically: people with liver disease or autoimmune conditions should not use giloy without medical supervision. If you develop jaundice, dark urine, persistent abdominal pain, or unusual fatigue after using it, stop and get prompt medical care. Separately, the HIV trial reported complaints of anorexia, nausea, vomiting, and weakness, and long-term safety data for giloy in humans are lacking. The allergic-rhinitis trial reported the extract as well tolerated (Badar et al.).

FAQs

Does giloy boost immunity?

There is no clinical-trial evidence that giloy improves immune function or prevents illness in humans. Most giloy research is preclinical (cells and animals), and a 2022 multicenter study concluded there is "no strong evidence for use in humans to prevent or treat any disease" (Hepatology Communications). "Immune booster" is a marketing claim, not a proven effect.

Does giloy help allergies or hay fever?

One small eight-week randomized, double-blind, placebo-controlled trial of 75 patients found improvement in sneezing, nasal discharge, obstruction, and itching (Badar et al.), a finding a phytotherapy review also cites (Springer review). This is promising but preliminary: a single small trial from 2005 that needs replication.

Can giloy damage the liver?

Yes: liver injury after giloy use is documented. A 2021 series reported six patients with autoimmune-like hepatitis (J Clin Exp Hepatol), and a 2022 multicenter study of 43 patients found acute hepatitis, worsening chronic liver disease, and acute liver failure, with probable causality in 67.4% and median onset 46 days after starting giloy (Hepatology Communications). People with liver disease should avoid it.

Can giloy treat COVID-19 or viral infections?

No clinical evidence supports giloy for preventing or treating viral infections, including COVID-19. It was marketed as an "immune-booster" during the pandemic (Hepatology Communications), but no trial establishes such an effect.

Is giloy safe to take daily?

Long-term safety in humans is not established, and liver-injury reports are the main concern. Do not use it daily on your own, especially with liver disease, autoimmune conditions, or other medications: discuss it with a clinician first.

What is the right dose of giloy?

No pharmacopoeial or well-documented trial dose was identified from authoritative sources, and products differ widely. There is no evidence-backed dose to recommend; talk to a qualified clinician rather than guessing.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.